patients and 55 darbepoetin alfa patients. duration of therapy was 13.2 weeks and 13.6 weeks in the epoetin
The .gov means its official. endobj
If patient has not responded satisfactorily to a 300 unit/kg dose 3 times/week, a response to higher doses is unlikely. alfa for chronic anemia of cancer and chemotherapy-induced anemia
affinity has no or little clinical relevance. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. During the first several months following initiation of RETACRIT, monitor patients closely for premonitory neurologic symptoms. Providers who prefer to use epoetin alfa-epbx must specify a reason for its use. >/@tCh;6|{rf9V8&Wb~%l7JNCcoi AkrJ.ttbdq5QSu+r|0&OhF]{.r!r
SN:]AW&g{auwi(D)Si'(EK 9P$a8d_R/au&tIk=[A'"Uh
5E~"{dC4dMs/*e?&Io}a\d05zVJ)~OL:MK'tiM>)r4zoBp`Vju`'78f4*q-PFa_,R2(r\?ASM^B6DT&s+IfUSqS6H5l~b)lMx:'j_sT[.q"ju g/8f5>tWw]}vAQNK0:
st3pYBMf7m\tHC6l#C(!%J[l6(d/$Apx>GW mo^6*{INX%!ZuH@=_c Dosage adjustment: Goal: Dose should be adjusted to achieve and maintain a target hemoglobin not to exceed 12 g/dL. When switched from the reference epoetin, the majority of subjects (61.8 %) received another patented epoetin and 38.2 % received a biosimilar epoetin. The assessment will also assess whether the reviewed drugs are likely to be considered good value for money for the NHS. Copyright 1993-2021 Dr. Gerald Diaz @GeraldMD. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Use the lowest dose of Aranesp necessary to avoid RBC transfusions. A target
Based on the patient's response, darbepoetin
Epub 2016 Mar 4. RETACRIT single-dose vials contain phenylalanine, a component of aspartame. official website and that any information you provide is encrypted A local search option of this data can be found here. Decreases in dose can occur more frequently. Last updated on Jan 20, 2023. Coverage Limitations Treatment with Darbepoetin alfa (Aranesp), Epoetin alfa (Procrit), Epoetin alfa (Epogen), and Epoetin alfa-epbx (Retacrit) is not considered medically necessary for members with the following concomitant conditions: Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis. Children: 75-100 mcg/kg once daily for 10-21 days (until postnadir platelet count >/= 50,000 cells/ uL). of endogenous erythropoietin may be impaired in patients receiving
Monitoring Parameters Complete blood count and platelet count should be obtained prior to chemotherapy. Before prescribing RETACRIT single-dose vials to a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including RETACRIT, Patients may require adjustments in their dialysis prescriptions after initiation of RETACRIT. EPOETIN ALFA-EPBX, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 . Although these images are curated, as they are sourced from the community, there is no way to guarantee a consistent standard of accuracy and quality across the library of images. conversion factor of 1 mcg:220 units Aranesp:EPO. Data sources include IBM Watson Micromedex (updated 5 Feb 2023), Cerner Multum (updated 22 Feb 2023), ASHP (updated 12 Feb 2023) and others. Conclusion: Advise patients of the importance of compliance with antihypertensive therapy and dietary restrictions, Epoetin alfa products, including RETACRIT, increase the risk of seizures in patients with CKD. For adult patients with CKD not on dialysis: When treating patients who have chronic kidney disease and cancer, physicians should refer to Warnings and Precautions (5.1 and 5.2). If patient does not respond, a response to higher doses is unlikely. Severe chronic neutropenia: Congenital: 6 mcg/kg twice daily Idiopathic/cyclic: 5 mcg/kg/day, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9222, Supplied: Injection, solution [preservative free]: 300 mcg/mL (1 mL, 1.6 mL) [vial; contains sodium 0.035 mg/mL and sorbitol], Injection, solution [preservative free]: 600 mcg/mL (0.5 mL, 0.8 mL) [prefilled Singleject syringe; contains sodium 0.035 mg/mL and sorbitol], Drug UPDATES: ZARXIO - filgrastim-sndz injection [Drug information / PDF] Click link for the latest monographDosing: Click (+) next to Dosage and Administration section (drug info link). HHS Vulnerability Disclosure, Help Severe sickle cell crises, in some cases resulting in death, have also been associated with Filgrastim, the parent compound of pegfilgrastim. An official website of the United States government, Recalls, Market Withdrawals and Safety Alerts, FDA approves first epoetin alfa biosimilar for the treatment of anemia, FDA: Office of Hematology and Oncology Products. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known, Phenylalanine can be harmful to patients with phenylketonuria (PKU). PATIENTS RECEIVING NEULASTA WHO REPORT LEFT UPPER ABDOMINAL AND/OR SHOULDER TIP PAIN SHOULD BE EVALUATED FOR AN ENLARGED SPLEEN OR SPLENIC RUPTURE. Neulasta should be permanently discontinued in patients with serious allergic reactions. every-other-week) for darbepoetin alfa-treated patients. In rare cases, allergic reactions including anaphylaxis, recurred within days after initial anti-allergic treatment was discontinued. In CKD, for subcutaneous (SC) administration
Excessive responses: Hemoglobin increases >1 g/dL in a 2-week period OR if hemoglobin exceeds 12 g/dL: Reduce dose by 25% Hemoglobin >13 g/dL: Withhold dose until hemoglobin falls to 12 g/dL, then reinitiate at 25% less than previous dose. The probability of switching between different epoetins was associated with the duration of treatment: about 15 % of users switched within 12 months and almost 25 % within 2 years of observation. Background: hbbd```b``IA$/f?W$_d6X&LE@${`lktfu` : 6C(XlB3XDD&iMt#K/X=(IW? l maintain desired hemoglobin (Hgb) levels. OMONTYS has not been shown to improve symptoms, physical functioning or health-related quality of life. The intravenous route is recommended for patients on hemodialysis. Non-hematopoietic pathologic changes observed in animals include fibrosis of tendons and joint capsules, periosteal thickening, papilledema, and embryotoxicity. Northwest Kidney Centers Home Dialysis Programs Standing Orders - Erythropoietin . Resources for Information | Approved Drugs, Recalls, Market Withdrawals and Safety Alerts, Resources for Information | Approved Drugs, Oncology (Cancer) / Hematologic Malignancies Approval Notifications, Verified Clinical Benefit | Cancer Accelerated Approvals, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description, FDA approves Retacrit as a biosimilar to Epogen/Procrit, Drug Information Soundcast in Clinical Oncology. Monitor platelets and hematocrit regularly. Use the lowest OMONTYS dose sufficient to reduce the need for red blood cell (RBC) transfusions. The most common side effects of epoetin alfa-treated patients in clinical studies of the reference product were high blood pressure, joint pain, muscle spasm, fever, dizziness, medical device malfunction, blood vessel blockage, respiratory infection, cough, rash, injection site irritation, nausea, vomiting, muscle pain, inflammation of the mouth and lips, weight decrease, reduction in white blood cells, bone pain, high blood sugar, insomnia, headache, depression, difficulty swallowing, low blood potassium, blood clots, itching, headache, injection site pain and chills. adverse event to Retacrit (epoetin alfa), and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information; OR For patients that are currently on treatment with Aranesp (darbepoetin alfa) they can remain on therapy. In addition, at this time, this interchange program does not affect
G-CSF is not species-specific and has been shown to have minimal direct in vivo or in vitro effects on the production or activity of hematopoietic cell types other than the neutrophil lineage. The dose conversion depicted in Table 1 does not accurately estimate the once monthly dose of Aranesp. Use caution in patients with coexistent cardiovascular disease and stroke. This site is intended only for U.S. healthcare professionals. If there are still air bubbles, repeat the steps above to remove them. Biological products are generally derived from a living organism and can come from many sources, such as humans, animals, microorganisms or yeast. Conversion from Another ESA: dosed once every 4 weeks based on total were 9.95 g/dL and 9.80 g/dL in the epoetin alfa- and darbepoetin
Please enable it to take advantage of the complete set of features! For recommended dose equivalency,
Adults: 50 mcg/kg once daily for 10-21 days (until postnadir platelet count >/= 50,000 cells/uL). 4y\@:hT4\j
EvZ%fN1gtL|;`,% \ZPrC|.CtI8K,f^f#.PJ#|CZx~igq\jA@PPq. Pussell BA, Walker R; Australian Renal Anaemia Group. %PDF-1.5
If hemoglobin continues to increase, hold dose temporarily until hemoglobin begins to decrease, then restart at a dose 25% below the previous dose. The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses. Mechanism of Action: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation differentiation commitment and some end-cell functional activation. Dosage adjustment: Goal: Dose should be adjusted to achieve and maintain a target hemoglobin not to exceed 12 g/dL. Q#(@$c *)[-Z-4jtLa-VA&N,1 J"/aNq~tY=r/?wMMOGsq/RJVsj{4p)3$J@jHy\}[AA$AFa>()RQ`20L=Rw8~v9u CONTRAINDICATIONS Neumega is contraindicated in patients with a history of hypersensitivity to Neumega or any component of the product, Dosage SubQ: Note: First dose should not be administered until 24-36 hours after the end of chemotherapy. Drug class: Recombinant human erythropoietins. A total of
Administer Aranesp once every 2 weeks in patients who were receiving epoetin alfa once weekly. In the near future, the Pharmacy and Therapeutics
of Pharmacy Drug Information Center (216-444-6456, option #1). (CIA) for both outpatients and inpatients. number of patients receiving transfusions, to increase hemoglobin
A brochure to help you understand how to dose and administer Aranesp, and to convert from epoetin alfa to Aranesp in patients with anemia due to CKD. This has been reported predominantly in patients with CKD receiving ESAs by subcutaneous administration. IL-11 has also been shown to have non-hematopoietic activities in animals including the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis, inhibition of pro-inflammatory cytokine production by macrophages, and the stimulation of osteoclastogenesis and neurogenesis. Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur with epoetin alfa products. Follow the Oncology Center of Excellence on Twitter @FDAOncology. GrepMed and the images sourced through this website are NOT a substitute for clinical judgement. both groups iron studies were not conducted routinely. Accessibility 600 Units/kg subcutaneously in 4 doses administered 21, 14, and 7 days before surgery and on the day of surgery. 1. Conversion - Epoetin alfa (Procrit) to Darbepoetin alfa (Aranesp) #Epoetin #Darbepoetin #Erythropoietin #Conversion #Table #ESAs #Procrit #Aranesp #Pharmacology #Hematology #Nephrology. W bO? This website was made to assist in clinical knowledge recall and to supplement and support clinician judgement. The most common dosing regimens are 40,000 units weekly for epoetin alfa and 200 mcg every 2 weeks for darbepoetin alfa. While a discounted alternative to Epogen and Procrit is welcome, there is a catch. for the erythropoietin receptors, suggesting the slower clearance
%PDF-1.6
%
Wien Med Wochenschr. Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) Discontinue RETACRIT therapy immediately if a severe cutaneous reaction, such as SJS/TEN, is suspected, RETACRIT from multiple-dose vials contains benzyl alcohol and is contraindicated for use in neonates, infants, pregnant women, and lactating women. epoetin alfa (3 N-linked CHO chains). Conversion from Epoetin alfa to Aranesp in patients with CKD on dialysis . Darbepoetin alfa (5 N-linked
OHSU's formulary erythropoiesis stimulating agent (ESA) is darbepoetin alfa (ARANESP). The optimal timing and duration of growth factor stimulation has not been determined. Stop dose if hemoglobin exceeds 13 g/dl and resume treatment at a 25% dose reduction when hemoglobin drops to 12 g/dl. startxref lNY0?j/0a6d%J1\3\qdS@*_gy{sl?!H^]ibQ'_(%`lI$5.r U ?Xz:sf;{@(eHB VII, No. Neumega is not indicated following myeloablative chemotherapy (see package insert for WARNINGS, Increased Toxicity Following Myeloablative Therapy). (CKD) patients, darbepoetin alfa administered intravenously has
1 0 obj
For patients who do not respond adequately, if the hemoglobin has not increased by more than 1 g/dL after 4 weeks of therapy, increase the dose by 25%. Pull the plunger back to the number on the syringe that matches your dose. The recommended starting dose is 0.45 mcg/kg intravenously or subcutaneously as a weekly injection or 0.75 mcg/kg once every 2 weeks as appropriate. As a substitute for RBC transfusions in patients who require immediate correction of anemia. When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly. Pronai W, Neyer U, Barnas U, Wieser C, Jaeger C, Dekic D, Hemetsberger M, Rosenkranz AR. A biosimilar is a biological product that is approved based on data showing that it is highly similar to a biological product already approved by the FDA (reference product) and has no clinically meaningful differences in terms of safety, purity and potency (i.e., safety and effectiveness) from the reference product, in addition to meeting other criteria specified by law. Sickle Cell Disease Severe sickle cell crises have been associated with the use of Neulasta in patients with sickle cell disease. in Hgb of 2 g/dL from baseline. In pediatric patients, Mircera is administered by intravenous injection only (2.2). of the molecule is a more important determinant of potency and receptor
PenTAG FINAL PROTOCOL 2 darbepoetin alfa (Aranesp [Amgen]). erythropoietin, darbepoetin alfa stimulates erythropoiesis. In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL. alfa-treated patients, respectively. The safety and effectiveness of Neumega have not been established in pediatric patients. FOIA patients had to be initiated on epoetin alfa or darbepoetin alfa
Full Prescribing Information, including BOXED WARNINGS, full Prescribing Information, including BOXED WARNINGS, Neonates, infants, pregnant women, and lactating women. deemed epoetin alfa (Procrit; OrthoBiotech) and darbepoetin
Note: The manufacturer states that, until efficacy/toxicity parameters are established, the use of oprelvekin in pediatric patients (particularly those <12 years of age) should be restricted to use in controlled clinical trials. epoetin alfa and darbepoetin alfa, have been shown to decrease the
Call 1-888-4ASSIST to find out more. Protect vials and prefilled syringes from light. 4. These adverse reactions included myocardial infarction and stroke, In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures, ESAs resulted in decreased locoregional control/progression-free survival (PFS) and/or overall survival (OS). _
p8"&JjyfEMeRid=D fGKD 8qwR^{c`KNp% Kvu%Q rH]Y "[/|O"1S|FVA@-G%#&DOks]Qf/YQj*$K) Pfizer for Professionals 1-800-505-4426 The
Individualize dosing and use the lowest dose of Aranesp sufficient to reduce the need for RBC transfusions [see Warnings and Precautions (5.1)]. most common dosing regimens are 40,000 units weekly for epoetin
Conversion from another ESA: dose once monthly based on the total weekly epoetin or darbepoetin alfa dose at the time of conversion. Reduce or withhold RETACRIT if blood pressure becomes difficult to control. Peripheral blood progenitor cell (PBPC) collection: 10 mcg/kg/day or 5-8 mcg/kg twice daily in donors. Previous dosage of epoetin alfa: 5000-10,999 units/week,then darbepoetin alfa dosage: 25 mcg/week. The
scMJkP`@SzQ`
o3O3Dl6o
8QT-]FjOPa\}m-6(L MAK{kFW-A3]dM36
m7L\|oPC(Y^ K%!Tx#Cgp+P=g-nKgan9ae2UM{kH9z;j8rq!J@ RETACRIT is a registered trademark of Pfizer Inc. Epogen is a registered trademark of Amgen Inc. Procrit is a registered trademark of Janssen Products, LP. Like Epogen/Procrit, Retacrit must be dispensed with a patient Medication Guide that provides information about the drugs uses and risks. The original dosage reduction after the switch from epoetin alfa to weekly intravenous darbepoetin alfa may offset the increased relative cost of the latter. 11 in the epoetin alfa-treated group and 7 in the darbepoetin alfa-treated
of darbepoetin administered SC has been shown in cancer patients
8600 Rockville Pike . Preclinical trials have shown that mature megakaryocytes which develop during in vivo treatment with Neumega are ultrastructurally normal. If a patient or caregiver experiences difficulty measuring the required dose, especially if it is other than the entire contents of the Aranesp prefilled syringe, use of the Aranesp vial may be considered. alfa- and darbepoetin alfa-treated patients, respectively. Careers. 2009 Oct;2(5):347-53. doi: 10.1093/ndtplus/sfp097. and 24 patients in the darbepoetin alfa group reached the targeted
Committee will be exploring other patient populations for this
More specifically, 23 patients in the epoetin alfa group
The needle cover of the prefilled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions. A single hemoglobin excursion may not require a dosing change. Check out recent approvals at the OCEs podcast, Drug Information Soundcast in Clinical Oncology. Generic name: DARBEPOETIN ALFA 10ug in 0.4mL Dose adjustment: If response is not satisfactory after a sufficient period of evaluation (8 weeks of 3 times/week and 4 weeks of once weekly therapy), the dose may be increased every 4 weeks (or longer) up to 300 units/kg 3 times/week, or when dosed weekly, increased all at once to 60,000 units weekly. An official website of the United States government, : Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. G-CSF is not species specific and has been shown to have minimal direct in vivo or in vitro effects on the production of hematopoietic cell types other than the neutrophil lineage. Copyright 2021 GlobalRPH - Web Development by, HONcode standard for trust- worthy health, Pediatric Oncology: Diagnosis And Prognosis Communication. 1. Conversion from Epoetin alfa to Aranesp in patients with CKD not on dialysis. adverse event to Retacrit (epoetin alfa), and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information; OR For patients that are currently on treatment with Aranesp (darbepoetin alfa) they can remain on Overall, in both groups iron studies were not conducted routinely. b. 114 (n=92 CCF) patients were included in the DUE, 59 epoetin alfa
IV
Epoetin alfa-epbx (Retacrit) will be approved through clinical review up to a 12-month determination. There is a potential for similar risks to fetuses and infants exposed to benzyl alcohol in utero or in breastfed milk, respectively. Epoetin alfa (Epogen, Procrit) and its biosimilar, epoetin alfa-epbx (Retacrit), are erythropoiesis-stimulating agents (ESAs). Epogen (epoetin alfa)injection, for intravenous or subcutaneous use Initial U.S.Approval: 1989 WARNING:ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. The recommended conversion dose for changing from epoetin alfa to darbepoetin alfa is 200 units to 1 microg. The agency also is responsible for the safety and security of our nations food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. Increase dose by 50-100 units/kg 3 times/week if response is not satisfactory in terms of reducing transfusion requirements or increasing hemoglobin after 8 weeks of therapy. 2007 Apr;12(2):126-9. doi: 10.1111/j.1440-1797.2006.00762.x. Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, Tak Piech C. Curr Med Res Opin. in patients with chronic anemia of cancer as well as CIA document
<>
CONTRAINDICATIONS Neulasta is contraindicated in patients with known hypersensitivity to E coli-derived proteins pegfilgrastim Filgrastim, or any other component of the product. Both Retacrit and Procrit are approved for treatment of anemia caused by chronic kidney disease, chemotherapy, use of zidovudine in patients with HIV, and before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. The protocol for anaemia management included a target haemoglobin (Hb) concentration of 120-130 g/L and a ferritin of 300-600 microg/L. This site needs JavaScript to work properly. !SSe@}vd^W7y% Qf={kGNyHD{9y`S [E^`G,PmN+`R)7oR'=. dbc&@hlv}t``t_/d+)X
T]{oF`S}+c|yt}
}
;X'~'6S;3$]K$t/Z1hrL;\qdHBwtKwHUL`
z0
DY%--V! Estimated Aranesp Starting Doses (mcg/week) for Patients with CKD on Dialysis Based on Previous Epoetin alfa Dose (Units/week), Previous Weekly Epoetin alfa Dose (Units/week). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. active than epoetin alfa, paradoxically was found to have less affinity
WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE. "9hu2,yUHZC]r}P(j 5{O$Mv$5O6
r~_RMN: 2YSkk.g_GCUswyDxD5m#):`1#V0O_>$gpz~Q5I^D6u'R52O Ou>dteJB* 1.3 Patients with Cancer Undergoing Bone Marrow Transplantation ZARXIO is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae e.g.febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3)]. The dose should be titrated to meet and
2 0 obj
4 x previous weekly epoetin alfa dose (Units)/125. Overall, in
Conclusion: In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. Based on the patient's response, darbepoetin alfa may be administered as frequently as once every 3 or 4 weeks.
Alma Lopez And Michael Naccari Still Married,
James River Church Speaking In Tongues,
Articles A